BL
Therapeutic Areas
Biogen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lecanemab (Leqembi) | Alzheimer's Disease | Marketed/Phase 3 |
| Aducanumab (Aduhelm) | Alzheimer's Disease | Marketed |
| BIIB080 / BIIB113 (Tau ASO) | Alzheimer's Disease | Phase 2 |
| Tofersen (Qalsody) | SOD1-ALS | Marketed |
| BIIB105 (ATXN2 ASO) | ALS | Phase 2 |
| Friedreich Ataxia Treatment | Friedreich Ataxia | Marketed |
| HI-Bio Portfolio Assets | Immune-Mediated Kidney Diseases | Phase 3 |
| Lupus Program | Lupus / SLE | Phase 3 |